Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
- PMID: 8710899
- PMCID: PMC38701
- DOI: 10.1073/pnas.93.16.8502
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
Abstract
The development of new capillary networks from the normal microvasculature of the host appears to be required for growth of solid tumors. Tumor cells influence this process by producing both inhibitors and positive effectors of angiogenesis. Among the latter, the vascular endothelial growth factor (VEGF) has assumed prime candidacy as a major positive physiological effector. Here, we have directly tested this hypothesis in the brain tumor, glioblastoma multiforme, one of the most highly vascularized human cancers. We introduced an antisense VEGF expression construct into glioblastoma cells and found that (i) VEGF mRNA and protein levels were markedly reduced, (ii) the modified cells did not secrete sufficient factors so as to be chemoattractive for primary human microvascular endothelial cells, (iii) the modified cells were not able to sustain tumor growth in immunodeficient animals, and (iv) the density of in vivo blood vessel formation was reduced in direct relation to the reduction of VEGF secretion and tumor formation. Moreover, revertant cells that recovered the ability to secrete VEGF regained each of these tumorigenic properties. These results suggest that VEGF plays a major angiogenic role in glioblastoma.
Similar articles
-
Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.Oncogene. 1999 Aug 26;18(34):4860-9. doi: 10.1038/sj.onc.1202869. Oncogene. 1999. PMID: 10490819
-
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.Am J Pathol. 1997 Dec;151(6):1523-30. Am J Pathol. 1997. PMID: 9403702 Free PMC article.
-
Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.Cancer Res. 1998 Sep 15;58(18):4185-92. Cancer Res. 1998. PMID: 9751633
-
[Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 Mar;34(2):165-70. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002. PMID: 12006990 Chinese.
-
Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.Jpn J Cancer Res. 1996 Sep;87(9):963-71. doi: 10.1111/j.1349-7006.1996.tb02127.x. Jpn J Cancer Res. 1996. PMID: 8878460 Free PMC article.
Cited by
-
Inhibition of vascular endothelial growth factor in the treatment of solid tumors.Curr Oncol Rep. 2002 Jan;4(1):20-8. doi: 10.1007/s11912-002-0044-9. Curr Oncol Rep. 2002. PMID: 11734110 Review.
-
Models for assessment of angiogenesis in gliomas.J Neurooncol. 2000 Oct-Nov;50(1-2):53-62. doi: 10.1023/a:1006462504447. J Neurooncol. 2000. PMID: 11245281 Review.
-
Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF.Br J Cancer. 2001 May 4;84(9):1252-7. doi: 10.1054/bjoc.2000.1734. Br J Cancer. 2001. PMID: 11336478 Free PMC article.
-
Anti-Invasion and Antiangiogenic Effects of Stellettin B through Inhibition of the Akt/Girdin Signaling Pathway and VEGF in Glioblastoma Cells.Cancers (Basel). 2019 Feb 14;11(2):220. doi: 10.3390/cancers11020220. Cancers (Basel). 2019. PMID: 30769863 Free PMC article.
-
Cloning and expression of the functional human anti-vascular endothelial growth factor (VEGF) using the pcDNA3.1 vector and the human chronic myelogenous leukemia cell line K562.Protein J. 2014 Feb;33(1):100-9. doi: 10.1007/s10930-013-9533-y. Protein J. 2014. PMID: 24399318
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources